CD40 and cardiovascular disorder: Despite all efforts, there is a possibility that a general, systemic CD40(L) blockade, while being suitable for the short-term treatment of exacerbations in autoimmune diseases, has limiting side effects in the long-term treatment of patients with cardiovascular disease (Figure 3).